BIORETEC OY (0TN) - Net Assets
Based on the latest financial reports, BIORETEC OY (0TN) has net assets worth €9.76 Million EUR (≈ $11.41 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.68 Million ≈ $13.65 Million USD) and total liabilities (€1.92 Million ≈ $2.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIORETEC OY asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €9.76 Million |
| % of Total Assets | 83.58% |
| Annual Growth Rate | 22.48% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 150.07 |
BIORETEC OY - Net Assets Trend (2021–2025)
This chart illustrates how BIORETEC OY's net assets have evolved over time, based on quarterly financial data. Also explore 0TN asset base for the complete picture of this company's asset base.
Annual Net Assets for BIORETEC OY (2021–2025)
The table below shows the annual net assets of BIORETEC OY from 2021 to 2025. For live valuation and market cap data, see 0TN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €9.76 Million ≈ $11.41 Million |
+0.24% |
| 2024-12-31 | €9.74 Million ≈ $11.38 Million |
+18.33% |
| 2023-12-31 | €8.23 Million ≈ $9.62 Million |
+328.41% |
| 2022-12-31 | €1.92 Million ≈ $2.25 Million |
-55.71% |
| 2021-12-31 | €4.34 Million ≈ $5.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BIORETEC OY's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2030337574.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €39.08 Million | 400.33% |
| Total Equity | €9.76 Million | 100.00% |
BIORETEC OY Competitors by Market Cap
The table below lists competitors of BIORETEC OY ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gale Pacific Ltd
AU:GAP
|
$16.11 Million |
|
Ark Mines Ltd
AU:AHK
|
$16.12 Million |
|
Vertice Bhd
KLSE:7240
|
$16.12 Million |
|
CPR Gomu Industrial PCL
BK:CPR
|
$16.13 Million |
|
Marvel Gold Ltd
AU:MVL
|
$16.10 Million |
|
Dongsung Pharm
KO:002210
|
$16.09 Million |
|
Arcure SA
PA:ALCUR
|
$16.09 Million |
|
TPC Co. Ltd
KQ:130740
|
$16.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIORETEC OY's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,738,211 to 9,762,000, a change of 23,789 (0.2%).
- Net loss of 9,482,731 reduced equity.
- New share issuances of 9,516,470 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-9.48 Million | -97.14% |
| Share Issuances | €9.52 Million | +97.48% |
| Other Changes | €-9.95K | -0.1% |
| Total Change | €- | 0.24% |
Book Value vs Market Value Analysis
This analysis compares BIORETEC OY's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.30 | €0.02 | x |
| 2022-12-31 | €0.13 | €0.02 | x |
| 2023-12-31 | €0.40 | €0.02 | x |
| 2024-12-31 | €0.40 | €0.02 | x |
| 2025-12-31 | €0.32 | €0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BIORETEC OY utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -269.27%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.20x
- Recent ROE (-97.14%) is below the historical average (-91.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -138.72% | -300.39% | 0.23x | 1.98x | €-6.45 Million |
| 2022 | -125.78% | -82.13% | 0.84x | 1.82x | €-2.61 Million |
| 2023 | -46.03% | -96.99% | 0.37x | 1.29x | €-4.61 Million |
| 2024 | -47.38% | -101.54% | 0.40x | 1.18x | €-5.59 Million |
| 2025 | -97.14% | -269.27% | 0.30x | 1.20x | €-10.46 Million |
Industry Comparison
This section compares BIORETEC OY's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $43,121,937,091
- Average return on equity (ROE) among peers: -25.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIORETEC OY (0TN) | €9.76 Million | -138.72% | 0.20x | $16.10 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $146.15K |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.77 Million | -198.14% | 0.62x | $28.30 Million |
| Medtronic PLC (2M6) | $15.97 Billion | 19.39% | 0.91x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.04 Billion | -11.08% | 0.32x | $401.71 Million |
| AVITA Medical Inc (51KB) | $84.74 Million | -31.47% | 0.16x | $172.49 Million |
| BRAINCOOL AB (5YL) | $145.93 Million | -30.32% | 0.11x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About BIORETEC OY
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; A… Read more